Limitations of current Parkinson's disease therapy

Annals of Neurology

Volumn 53, Issue SUPPL. 3, 2003, Pages

  Rascol, Olivier ^a,c   Payoux, Pierre ^a   Ory, Fabienne ^a   Ferreira, Joaquim J ^a,b   Brefel Courbon, Christine ^a   Montastruc, Jean Louis ^a   Schapira, ^b   Jenner, ^b   Tatton, ^b   Stocchi, ^b   Kordower, ^b   Olanow, ^b   Isacson, ^b   Beal, ^b  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

^b Department of Neurology ^*

^c UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTIPARKINSON AGENT; APOMORPHINE; BENZATROPINE; BIPERIDEN; BROMOCRIPTINE; CABERGOLINE; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLOZAPINE; DIHYDROERGOCRYPTINE; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; GLUTAMATE RECEPTOR ANTAGONIST; LEVODOPA; LISURIDE; MONOAMINE OXIDASE B INHIBITOR; PERGOLIDE; PIRIBEDIL; PRAMIPEXOLE; PROCYCLIDINE; RISPERIDONE; RIVASTIGMINE; ROPINIROLE; SELEGILINE; TOLCAPONE; TRIHEXYPHENIDYL; UNINDEXED DRUG;

ALOPECIA; AUTONOMIC DYSFUNCTION; BODY POSTURE; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; CONFUSION; CONSTIPATION; DEMENTIA; DEPRESSION; DIARRHEA; DISABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG SAFETY; DYSKINESIA; EDEMA; ERYTHROMELALGIA; HALLUCINATION; HUMAN; HYPOTENSION; INTRAOCULAR HYPERTENSION; LIVEDO RETICULARIS; LIVER TOXICITY; LUNG FIBROSIS; MOOD DISORDER; NAUSEA; NEUROPROTECTION; ORTHOSTATIC HYPOTENSION; PAIN; PARKINSON DISEASE; PHYSIOTHERAPY; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY; PSYCHOSIS; QUALITY OF LIFE; RETROPERITONEAL FIBROSIS; REVIEW; SIDE EFFECT; SLEEP DISORDER; SPEECH DISORDER; TREATMENT OUTCOME; URINE RETENTION; VOMITING; XEROSTOMIA;

ANTIPARKINSON AGENTS; COGNITION DISORDERS; DRUG RESISTANCE; DYSARTHRIA; DYSKINESIA, DRUG-INDUCED; ELECTRIC STIMULATION THERAPY; GLOBUS PALLIDUS; HUMANS; NEUROSURGICAL PROCEDURES; PARKINSON DISEASE; PSYCHOSES, SUBSTANCE-INDUCED; QUALITY OF LIFE; SUBTHALAMIC NUCLEUS;

EID: 0037378689     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.10513     Document Type: Review

References (101)

1. Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N Engl J Med 1967; 276:374-379.
2. Goetz C, Koller W, Poewe W, et al. Management of Parkinson's disease: an evidence-based review. Mov Disord 2002; 17(suppl 4):1-166.
3. Hughes AJ, Daniel SE, Lees AJ. Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology 2001; 57:1497-1499.
4. Agid Y, Cervera P, Hirsch E, et al. Biochemistry of Parkinson's disease 28 years later: a critical review. Mov Disord 1989;4:S126-S144.
5. Agid Y, Taquet H, Cesselin F, et al. Neuropeptides and Parkinson's disease. Prog Brain Res 1986;66:107-116.
6. Dubois B, Hauw JJ, Ruberg M, et al. [Dementia and Parkinson's disease: biochemical and anatomo-clinical correlation]. Rev Neurol 1985;141:184-193.
7. Pillon B, Dubois B, Cusimano G, et al. Does cognitive impairment in Parkinson's disease result from non-dopaminergic lesions? J Neurol Neurosurg Psychiatry 1989;52:201-206.
8. Wakabayashi K, Takahashi H. Neuropathology of autonomic nervous system in Parkinson's disease. Eur Neurol 1997;38:2-7.
9. Jankovic J, Kapadia AS. Functional decline in Parkinson disease. Arch Neurol 2001;58:1611-1615.
10. Gentil M, Pollak P, Perret J. Parkinsonian dysarthria. Rev Neurol (Paris) 1995;151:105-112.
11. Bloem BR, van Vugt JP, Beckley DJ. Postural instability and falls in Parkinson's disease. Adv Neurol 2001;87:209-223.
12. Giladi N, Kao R, Fahn S. Freezing phenomenon in patients with parkinsonian syndromes. Mov Disord 1997;12:302-305.
13. Giladi N. Gait disturbances in advanced stages of Parkinson's disease. Adv Neurol 2001;86:273-278.
14. Bonnet AM, Loria Y, Saint-Hilaire MH, et al. Does long-term aggravation of Parkinson's disease result from non dopaminergic lesions? Neurology 1987;37:1539-1542.
15. Ashburn A, Stack E, Pickering RM, Ward CD. A community-dwelling sample of people with Parkinson's disease: characteristics of fallers and non-fallers. Age Ageing 2001;30:47-52.
16. Senard JM, Rai S, Lapeyre-Mestre M, et al. Prevalence of orthostatic hypotension in Parkinson's disease. J Neurol Neurosurg Psychiatry 1997;63:584-589.
17. Senard JM, Brefel-Courbon C, Rascol O, Montastruc JL. Orthostatic hypotension in patients with Parkinson's disease: pathophysiology and management. Drugs Aging 2001;18:495-505.
18. Martignoni E, Pacchetti C, Godi L, et al. Autonomic disorders in Parkinson's disease. J Neural Transm Suppl 1995;45:11-19.
19. Mathias CJ. Disorders affecting autonomic function in parkinsonian patients. Adv Neurol 1996;69:383-391.
20. Chaudhuri KR. Autonomic dysfunction in movement disorders. Curr Opin Neurol 2001;14:505-511.
21. Cummings JL, Masterman DL. Depression in patients with Parkinson's disease. Int J Geriatr Psychiatry 1999;14:711-718.
22. Mayeux R, Denaro J, Hemenegildo N, et al. A population-based investigation of Parkinson's disease with and without dementia. Relationship to age and gender. Arch Neurol 1992; 49:492-497.
23. McKeith IG. Dementia with Lewy bodies. Br J Psychiatry 2002;180:144-147.
24. Lees AJ, Blackburn NA, Campbell VL. The nighttime problems of Parkinson's disease. Clin Neuropharmacol 1988;11:512-519.
25. Larsen JP, Tandberg E. Sleep disorders in patients with Parkinson's disease: epidemiology and management. CNS Drugs 2001;15:267-275.
26. Tan EK, Lum SY, Fook-Chong SM, et al. Evaluation of somnolence in Parkinson's disease: comparison with age- and sex-matched controls. Neurology 2002;58:465-468.
27. Waseem S, Gwinn-Hardy K. Pain in Parkinson's disease. Common yet seldom recognized symptom is treatable. Postgrad Med 2001;110:33-34,39-40,46.
28. Morrish PK, Rakshi JS, Bailey DL, et al. Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET. J Neurol Neurosurg Psychiatry 1998;64:314-319.
29. Olanow CW. Attempts to obtain neuroprotection in Parkinson's disease. Neurology 1997;49:S26-S33.
30. Drukarch B, van Muiswinkel FL. Neuroprotection for Parkinson's disease: a new approach for a new millennium. Expert Opin Invest Drugs 2001;10:1855-1868.
31. Palmer GC. Neuroprotection by NMDA receptor antagonists in a variety of neuropathologies. Curr Drug Targets 2001;2:241-271.
32. The Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993;328:176-183.
33. Olanow CW, Hauser RA, Gauger L, et al. The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann Neurol 1995;38:771-777.
34. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-442.
35. DATATOP. Mortality in DATATOP: a multicenter trial in early Parkinson's disease. Parkinson Study Group. Ann Neurol 1998;43:318-325.
36. Guttman M, Stewart D, Hussey D, et al. Influence of L-dopa and pramipexole on striatal dopamine transporter in early PD. Neurology 2001;56:1559-1564.
37. Lees AJ, Katzenschlager R, Head J, Ben-Shlomo Y. Ten-year follow-up of three different initial treatments in de-novo PD: a randomized trial. Neurology 2001;57:1687-1694.
38. Bodagh IY, Robertson DR. A risk-benefit assessment of drugs used in the management of Parkinson's disease. Drug Saf 1994;11:94-103.
39. Shill H, Stacy M. Respiratory function in Parkinson's disease. Clin Neurosci 1998;5:131-135.
40. Kaakkola S. Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease. Drugs 2000;59:1233-1250.
41. Tan EK, Ondo W. Clinical characteristics of pramipexole-induced peripheral edema. Arch Neurol 2000;57:729-732.
42. Alkhani A, Lozano AM. Pallidotomy for Parkinson disease: a review of contemporary literature. J Neurosurg 2001;94:43-49.
43. Factor SA, Molho ES, Podskalny GD, Brown D. Parkinson's disease: drug-induced psychiatric states. Adv Neurol 1995;65:115-138.
44. Obeso JA, Olanow CW, Nutt JG. Levodopa motor complications in Parkinson's disease. Trends Neurosci 2000;23:S2-S7.
45. Obeso JA, Rodriguez-Oroz MC, Chana P, et al. The evolution and origin of motor complications in Parkinson's disease. Neurology 2000;55:S13-S20; discussion, S21-S23.
46. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001;16:448-458.
47. Fabbrini G, Mouradian MM, Juncos JL, et al. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part I. Ann Neurol 1988;24:366-371.
48. Mouradian MM, Juncos JL, Fabbrini G, et al. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, Part II. Ann Neurol 1988;24:372-378.
49. Bravi D, Mouradian MM, Roberts JW, et al. Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms. Ann Neurol 1994;36:27-31.
50. Verhagen Metman L, Locatelli ER, Bravi D, et al. Apomorphine responses in Parkinson's disease and the pathogenesis of motor complications. Neurology 1997;48:369-372.
51. Olanow W, Schapira AH, Rascol O. Continuous dopaminereceptor stimulation in early Parkinson's disease. Trends Neurosci 2000;23:S117-S126.
52. Rascol O. L-dopa-induced peak-dose dyskinesias in patients with Parkinson's disease: a clinical pharmacologic approach. Mov Disord 1999;14:19-32.
53. Bezard E, Brotchie JM, Gross CE. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat Rev Neurosci 2001;2:577-588.
54. Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology 2001;56(suppl 5):1-88.
55. Lang AE, Lozano AM. Parkinson's disease. Second of two parts. N Engl J Med 1998;339:1130-1143.
56. Papa SM, Chase TN. Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys. Ann Neurol 1996;39:574-578.
57. Lang AE. Surgery for Parkinson disease: a critical evaluation of the state of the art. Arch Neurol 2000;57:1118-1125.
58. Rascol O, Goetz C, Koller W, et al. Treatment interventions for Parkinson's disease: an evidence based assessment. Lancet 2002;359:1589-1598.
59. Rascol O, Brooks DJ, Brunt ER, et al. Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year levodopa-controlled study. 056 Study Group. Mov Disord 1998;13:39-45.
60. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA 2000;284:1971-1973.
61. Melamed E, Offen D, Shirvan A, et al. Levodopa toxicity and apoptosis. Ann Neurol 1998;44:S149-S154.
62. Murer MG, Dziewczapolski G, Menalled LB, et al. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Ann Neurol 1998;43:561-575.
63. Agid Y, Olanow CW, Mizuno Y. Levodopa - why the controversy? Lancet 2002;360:575.
64. Barone P, Bravi D, Bermejo-Pareja F, et al. Pergolide monotherapy in the treatment of early PD: a randomized, controlled study. Pergolide Monotherapy Study Group. Neurology 1999;53:573-579.
65. Adler CH, Sethi KD, Hauser RA, et al. Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group. Neurology 1997;49:393-399.
66. Parkinson Study Group. Safety and efficacy of pramipexole in early Parkinson disease. A randomized dose-ranging study. Parkinson Study Group. JAMA 1997;278:125-130.
67. Corrigan MH, Denahan AQ, Wright CE, et al. Comparison of pramipexole, fluoxetine, and placebo in patients with major depression. Depress Anxiety 2000;11:58-65.
68. Guttman M. Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease. International Pramipexole-Bromocriptine Study Group. Neurology 1997;49:1060-1065.
69. Lieberman A, Olanow CW, Sethi K, et al. A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Ropinirole Study Group. Neurology 1998;51:1057-1062.
70. Colzi A, Turner K, Lees AJ. Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease. J Neurol Neurosurg Psychiatry 1998;64:573-576.
71. Stocchi F, Ruggieri S, Vacca L, Olanow CW. Prospective randomized trial of lisuride infusion versus oral levodopa in PD patients. Brain 2002;125:2058-2066.
72. Rascol O, Brooks DJ, Korczyn AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000;342:1484-1491.
73. Rinne UK, Bracco F, Chouza C, et al. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group. Drugs 1998;55:23-30.
74. Olanow CW, Jenner P, Brooks D. Dopamine agonists and neuroprotection in Parkinson's disease. Ann Neurol 1998;44:167-174.
75. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002;287:1653-1661.
76. Whone AL, Remy P, Davis MR, et al. The REAL-PET Study: slower progression in early Parkinson's disease treated with ropinirole compared with L-dopa. Neurology 2002;58:82-83.
77. Montastruc JL, Desboeuf K, Lapeyre-Mestre M, et al. Long-term mortality results of the randomized controlled study comparing bromocriptine to which levodopa was later added with levodopa alone in previously untreated patients with Parkinson's disease. Mov Disord 2001;16:511-514.
78. DATATOP. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Ann Neurol 1996;40:946-948.
79. Olanow CW. Selegiline: current perspectives on neuroprotection and mortality. Neurology 1996;47:210-216.
80. Maruyama W, Naoi M. Neuroprotection by (-)-deprenyl and related compounds. Mech Ageing Dev 1999;111:189-200.
81. Lees AJ. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom. Br Med J 1995;311:1602-1607.
82. Ben-Shlomo Y, Churchyard A, Head J, et al. Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry. Br Med J 1998;316:1191-1196.
83. Olanow CW, Myllyla VV, Sotaniemi KA, et al. Effect of selegiline on mortality in patients with Parkinson's disease: a meta-analysis. Neurology 1998;51:825-830.
84. Donnan PT, Steinke DT, Stubbings C, et al. Selegiline and mortality in subjects with Parkinson's disease: a longitudinal community study. Neurology 2000;55:1785-1789.
85. Assal F, Spahr L, Hadengue A, et al. Tolcapone and fulminant hepatitis. Lancet 1998;352:958.
86. Rinne UK, Larsen JP, Siden A, Worm-Petersen J. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group. Neurology 1998;51:1309-1314.
87. Parkinson Study Group. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann Neurol 1997;42:747-755.
88. Olanow CW, Obeso JA. Pulsatile Stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson's disease: implications for the early use of COMT Inhibitors. Neurology 2000;55:72-81.
89. Martin WE, Loewenson RB, Resch JA, Baker AB. A controlled study comparing trihexyphenidyl hydrochloride plus levodopa with placebo plus levodopa in patients with Parkinson's disease. Neurology 1974;24:912-919.
90. Verhagen Metman L, Del Dotto P, van den Munckhof P, et al. Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Neurology 1998;50:1323-1326.
91. Metman LV, Del Dotto P, LePoole K, et al. Amantadine for levodopa-induced dyskinesias: a 1-year follow-up study. Arch Neurol 1999;56:1383-1386.
92. Del Dotto P, Pavese N, Gambaccini G, et al. Intravenous amantadine improves levodopa-induced dyskinesias: an acute double-blind placebo-controlled study. Mov Disord 2001;16:515-520.
93. Uitti RJ, Rajput AH, Ahlskog JE, et al. Amantadine treatment is an independent predictor of improved survival in Parkinson's disease. Neurology 1996;46:1551-1556.
94. Olanow CW, Brin MF. Surgery for Parkinson's disease: a physician's perspective. Adv Neurol 2001;86:421-433.
95. The Deep-Brain Stimulation for Parkinson's Disease Study Group. Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease. N Engl J Med 2001;345:956-963.
96. Freed CR, Greene PE, Breeze RE, et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 2001;344:710-719.
97. Olanow CW. Transplantation for Parkinson's disease: pros, cons, and where do we go from here? Mov Disord 2002; 17(suppl 5):15.
98. McKeith I, Del Ser T, Spano P, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 2000;356:2031-2036.
99. The French Clozapine Parkinson Study Group. Clozapine in drug-induced psychosis in Parkinson's disease. The French Clozapine Parkinson Study Group. Lancet 1999;353:2041-2042.
100. The Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. The Parkinson Study Group. N Engl J Med 1999;340:757-763.
101. Goetz CG, Blasucci LM, Leurgans S, Pappert EJ. Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology 2000;55:789-794.